Critical Functions of the Lysosome in Cancer Biology

Annual Review of Pharmacology and Toxicology

Volumn 57, Issue , 2017, Pages 481-507

  Davidson, Shawn M ^a   Vander Heiden, Matthew G ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

cancer; cancer metabolism; hallmarks of cancer; lysosome function

Indexed keywords

ANGIOGENESIS; AUTOPHAGY; CANCER THERAPY; CELL DEATH; CELL DIVISION; CELL FUNCTION; CELL IMMORTALIZATION; CELL INVASION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; INFLAMMATION; LYSOSOME; MALIGNANT NEOPLASM; METASTASIS; MITOPHAGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; GENETICS; HOMEOSTASIS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; HOMEOSTASIS; HUMANS; LYSOSOMES; NEOPLASM INVASIVENESS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85009069310     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010715-103101     Document Type: Review

References (205)

1. Holtzman E. 1989. Lysosomes. New York: Plenum Press
2. Saftig P, Schröder B, Blanz J. 2010. Lysosomal membrane proteins: life between acid and neutral conditions. Biochem. Soc. Trans. 38:1420-23
3. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, et al. 2011. TFEB links autophagy to lysosomal biogenesis. Science 332:1429-33
4. Settembre C, Fraldi A, Medina DL, Ballabio A. 2013. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol. 14:283-96
5. Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, et al. 2012. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31:1095-108
6. Scriver CR. 2001. TheMetabolic&Molecular Bases of Inherited Disease.New York/Montreal: McGraw-Hill
7. Levine B, Kroemer G. 2008. Autophagy in the pathogenesis of disease. Cell 132:27-42
8. Kimmelman AC. 2011. The dynamic nature of autophagy in cancer. Genes Dev. 25:1999-2010
9. White E. 2015. The role for autophagy in cancer. J. Clin. Investig. 125:42-46
10. Kirkegaard T, JaätteläM. 2009. Lysosomal involvement in cell death and cancer. Biochim. Biophys. Acta 1793:746-54
11. Hanahan D,Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74
12. Raff MC. 1996. Size control: the regulation of cell numbers in animal development. Cell 86:173-75
13. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11:85-95
14. Boroughs LK, DeBerardinis RJ. 2015. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17:351-59
15. Goh LK, Sorkin A. 2013. Endocytosis of receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol. 5:a017459
16. Gschwind A, Fischer OM,Ullrich A. 2004. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4:361-70
17. Mellman I, Yarden Y. 2013. Endocytosis and cancer. Cold Spring Harb. Perspect. Biol. 5:a016949
18. Sorkin A, Fortian A. 2014. Endocytosis and endosomal sorting of receptor tyrosine kinases. In Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease, ed. DL Wheeler, Y Yarden, pp. 133-61. New York: Springer
19. Yamazaki T, Zaal K, Hailey D, Presley J, Lippincott-Schwartz J, Samelson LE. 2002. Role of Grb2 in EGF-stimulated EGFR internalization. J. Cell. Sci. 115:1791-802
20. Kowanetz K, Crosetto N, Haglund K, Schmidt MHH, Heldin C-H, Dikic I. 2004. Suppressors of T-cell receptor signaling Sts-1 and Sts-2 bind to Cbl and inhibit endocytosis of receptor tyrosine kinases. J. Biol. Chem. 279:32786-95
21. Elfenbein A, Lanahan A, Zhou TX, Yamasaki A, Tkachenko E, et al. 2012. Syndecan 4 regulates FGFR1 signaling in endothelial cells by directing macropinocytosis. Sci. Signal. 5:ra36
22. Schmees C, Villaseñor R, Zheng W, Ma H, Zerial M, et al. 2012. Macropinocytosis of the PDGF-receptor promotes fibroblast transformation by H-RasG12V. Mol. Biol. Cell 23:2571-82
23. Goldsmith J, Levine B, Debnath J. 2014. Autophagy and cancer metabolism. Methods Enzymol. 542:25-57
24. Mah LY, Ryan KM. 2012. Autophagy and cancer. Cold Spring Harb. Perspect. Biol. 4:a008821
25. Bergeron JJM, Di Guglielmo GM, Dahan S, Dominguez M, Posner BI. 2016. Spatial and temporal regulation of receptor tyrosine kinase activation and intracellular signal transduction. Annu. Rev. Biochem. 85:573-97
26. Goldenring JR. 2013. A central role for vesicle trafficking in epithelial neoplasia: intracellular highways to carcinogenesis. Nat. Rev. Cancer 13:813-20
27. Cuervo AM,Wong E. 2014. Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 24:92-104
28. LiangXH, Jackson S, SeamanM,Brown K, KempkesB, et al. 1999. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402:672-76
29. Feng Y, He D, Yao Z, Klionsky DJ. 2014. The machinery of macroautophagy. Cell Res. 24:24-41
30. Mathew R, Karantza-Wadsworth V, White E. 2007. Role of autophagy in cancer. Nat. Rev. Cancer 7:961-67
31. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, et al. 2015. Autophagy in malignant transformation and cancer progression. EMBO J. 34:856-80
32. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, et al. 2007. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 21:1367-81
33. Wei Y,Zou Z, Becker N, Anderson M, SumpterR, et al. 2013. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 154:1269-84
34. Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, et al. 2009. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat. Cell Biol. 11:385-96
35. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261-74
36. Shanware NP, Bray K, Abraham RT. 2013. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu. Rev. Pharmacol. Toxicol. 53:89-106
37. Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL. 2015. Identification of an oncogenic RAB protein. Science 350:211-17
38. Mousavi SA, Brech A, Berg T, Kjeken R. 2003. Phosphoinositide 3-kinase regulates maturation of lysosomes in rat hepatocytes. Biochem. J. 372:861-69
39. Luzio JP, Poupon V, Lindsay MR, Mullock BM, Piper RC, Pryor PR. 2003. Membrane dynamics and the biogenesis of lysosomes. Mol. Membr. Biol. 20:141-54
40. LiuK, Jian Y, SunX,YangC,Gao Z, et al. 2016. Negative regulation of phosphatidylinositol 3-phosphate levels in early-to-late endosome conversion. J. Cell Biol. 212:181-98
41. Dibble CC, Cantley LC. 2015. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 25:545-55
42. Hales EC, Taub JW, Matherly LH. 2014. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell. Signal. 26:149-61
43. Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274-93
44. Wang Y, Gao J, Guo X, Tong T, Shi X, et al. 2014. Regulation of EGFR nanocluster formation by ionic protein-lipid interaction. Cell Res. 24:959-76
45. Valley CC, Lidke KA, Lidke DS. 2014. The spatiotemporal organization of ErbB receptors: insights from microscopy. Cold Spring Harb. Perspect. Biol. 6:a020735
46. Wang C, Wang Y, Li Y, Bodemann B, Zhao T, et al. 2015. A nanobuffer reporter library for fine-scale imaging and perturbation of endocytic organelles. Nat. Commun. 6:8524
47. Yang ZJ, Chee CE, Huang S, Sinicrope FA. 2011. The role of autophagy in cancer: therapeutic implications. Mol. Cancer Ther. 10:1533-41
48. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-33
49. Son J, Lyssiotis CA, Ying H,Wang X, Hua S, et al. 2013. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496:101-
50. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. 2008. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7:11-20
51. Hosios AM, Hecht VC, Danai LV, Johnson MO, Rathmell JC, et al. 2016. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev. Cell 36:540-49
52. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, et al. 2013. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497:633-37
53. Haigler HT, McKanna JA, Cohen S. 1979. Rapid stimulation of pinocytosis in human carcinoma cells A-431 by epidermal growth factor. J. Cell Biol. 83:82-90
54. Lewis WH. 1937. Pinocytosis by malignant cells. Cancer Res. 29:666-79
55. Mosesson Y, Mills GB, Yarden Y. 2008. Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer 8:835-50
56. Bar-SagiD, Feramisco JR. 1986. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 233:1061-68
57. Kamphorst JJ, NofalM, Commisso C, Hackett SR, Lu W, et al. 2015. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 75:544-53
58. Young RM, Ackerman D, Quinn ZL, Mancuso A, Gruber M, et al. 2013. Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev. 27:1115-31
59. Kamphorst JJ, Cross JR, Fan J. 2013. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. PNAS 110:8882-87
60. Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. 2015. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell 162:259-70
61. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, et al. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC, but not S6K1. Dev. Cell 11:859-71
62. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, et al. 2005. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120:237-48
63. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, et al. 2004. The role of autophagy during the early neonatal starvation period. Nature 432:1032-36
64. Hecht VC, Sullivan LB, Kimmerling RJ, Kim D-H, Hosios AM, et al. 2016. Biophysical changes reduce energetic demand in growth factor-deprived lymphocytes. J. Cell Biol. 212:439-47
65. Chourasia AH, Boland ML, Macleod KF. 2015. Mitophagy and cancer. Cancer Metab. 3:4
66. Youle RJ, Narendra DP. 2011. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12:9-14
67. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, et al. 2013. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 27:1447-61
68. Hughes AL, Gottschling DE. 2012. An early age increase in vacuolar pH limits mitochondrial function and lifespan in yeast. Nature 492:261-65
69. Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE. 2013. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 36:65-71
70. Mochida K, Oikawa Y, Kimura Y, Kirisako H, Hirano H, et al. 2015. Receptor-mediated selective autophagy degrades the endoplasmic reticulum and the nucleus. Nature 522:359-62
71. Khaminets A, Heinrich T, Mari M, Grumati P, Huebner AK, et al. 2015. Regulation of endoplasmic reticulum turnover by selective autophagy. Nature 522:354-58
72. Sumpter R Jr., Sirasanagandla S, Fernández Á F,Wei Y, Dong X, et al. 2016. Fanconi anemia proteins function in mitophagy and immunity. Cell 165:867-81
73. Wang S, Tsun Z-Y, Wolfson RL, Shen K, Wyant GA, et al. 2015. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 347:188-94
74. Rebsamen M, Pochini L, Stasyk T, de AraujoMEG, Galluccio M, et al. 2015. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 519:477-81
75. Wolfson RL, Chantranupong L, Saxton RA, Shen K, Scaria SM, et al. 2016. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 351:43-48
76. Chantranupong L, Scaria SM, Saxton RA, Gygi MP, Shen K, et al. 2016. The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell 165:153-64
77. Settembre C, Ballabio A. 2014. Lysosome: regulator of lipid degradation pathways. Trends Cell Biol. 24:743-50
78. Efeyan A,CombWC, Sabatini DM. 2015. Nutrient-sensing mechanisms and pathways. Nature 517:302-10
79. Argilés JM, Busquets S, Stemmler B, Ĺ opez-Soriano FJ. 2014. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14:754-62
80. Mayers JR, Wu C, Clish CB, Kraft P, TorrenceME, et al. 2014. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med. 20:1193-98
81. Covini D, Tardito S, Bussolati O, Chiarelli LR, Pasquetto MV, et al. 2012. Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat. Anticancer Drug Discov. 7:4-13
82. Koivusalo M, Welch C, Hayashi H, Scott CC, Kim M, et al. 2010. Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling. J. Cell Biol. 188:547-63
83. Vander Heiden MG. 2013. Exploiting tumor metabolism: challenges for clinical translation. J. Clin. Investig. 123:3648-51
84. Piao S, Amaravadi RK. 2015. Targeting the lysosome in cancer. Ann. N. Y. Acad. Sci. 1371:45-54
85. McDuff FKE, Turner SD. 2011. Jailbreak: oncogene-induced senescence and its evasion. Cell. Signal. 23:6-13
86. Braig M, Lee S, LoddenkemperC,Rudolph C, Peters AHFM, et al. 2005. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436:660-65
87. Chen Z, Trotman LC, Shaffer D, Lin H-K,Dotan ZA, et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-30
88. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, et al. 2005. Tumour biology: senescence in premalignant tumours. Nature 436:642
89. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, et al. 2006. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10:459-72
90. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21:379-84
91. Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, et al. 2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-24
92. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. 2007. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 9:493-505
93. Lee BY, Han JA, Im JS, Morrone A, Johung K, et al. 2006. Senescence-associated-galactosidase is lysosomal-galactosidase. Aging Cell 5:187-95
94. Kurz DJ, Decary S, Hong Y, Erusalimsky JD. 2000. Senescence-associated-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell. Sci. 113(Pt 20):3613-22
95. Pérez-Mancera PA, Young ARJ, Narita M. 2014. Inside and out: the activities of senescence in cancer. Nat. Rev. Cancer 14:547-58
96. Ros S, Schulze A. 2012. Linking glycogen and senescence in cancer cells. Cell Metab. 16:687-88
97. Gey C, Seeger K. 2013. Metabolic changes during cellular senescence investigated by proton NMRspectroscopy. Mech. Ageing Dev. 134:130-38
98. Aird KM, Zhang R. 2015. Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett. 356:204-10
99. Ivanov A, Pawlikowski J, Manoharan I, van Tuyn J, Nelson DM, et al. 2013. Lysosome-mediated processing of chromatin in senescence. J. Cell Biol. 202:129-43
100. Allison AC. 1974. Lysosomes in cancer cells. J. Clin. Pathol. Suppl. 7:43-50
101. Kroemer G, JaätteläM. 2005. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 5:886-97
102. Roczniak-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, et al. 2012. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci. Signal. 5:ra42
103. Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, et al. 2015. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature 524:361-65
104. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, et al. 2009. A gene network regulating lysosomal biogenesis and function. Science 325:473-77
105. Andrews NW, Almeida PE, Corrotte M. 2014. Damage control: cellular mechanisms of plasma membrane repair. Trends Cell Biol. 24:734-42
106. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. 2011. Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 11:503-11
107. Krtolica A, Parrinello S, Lockett S,Desprez PY, Campisi J. 2001. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. PNAS 98:12072-77
108. Parrinello S, Coppe J-P, Krtolica A, Campisi J. 2005. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell. Sci. 118:485-96
109. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. 2010. The essence of senescence. Genes Dev. 24:2463-79
110. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. 1995. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10:1725-29
111. De Souza AT, Hankins GR, Washington MK, Orton TC. 1995. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat. Genet. 11:447-49
112. Mills JJ, Falls JG, De Souza AT, Jirtle RL. 1998. Imprinted M6p/Igf2 receptor is mutated in rat liver tumors. Oncogene 16:2797-802
113. Kornfeld S. 1992. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu. Rev. Biochem. 61:307-30
114. Kreiling JL, Montgomery MA,Wheeler JR, Kopanic JL, Connelly CM, et al. 2012. Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer. FEBS J. 279:2695-713
115. Hoyo C, Murphy SK, Schildkraut JM, Vidal AC, Skaar D, et al. 2012. IGF2R genetic variants, circulating IGF2 concentrations and colon cancer risk in African Americans and Whites. Dis. Markers 32:133-41
116. Cheng I, Stram DO, Burtt NP, Gianniny L, Garcia RR, et al. 2009. IGF2R missense single-nucleotide polymorphisms and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomark. Prev. 18:1922-24
117. Tian Z, Yao G, Song H, Zhou Y, Geng J. 2014. IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. Cell. Physiol. Biochem. 34:1578-88
118. Tasdemir E, Maiuri MC, Morselli E, Criollo A. 2008. A dual role of p53 in the control of autophagy. Autophagy 4:1-5
119. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, et al. 2013. p53 status determines the role of autophagy in pancreatic tumour development. Nature 504:296-300
120. Yang S, Wang X, Contino G, Liesa M, Sahin E, et al. 2011. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25:717-29
121. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, et al. 2014. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 4:905-13
122. Liang C, Jung JU. 2010. Autophagy genes as tumor suppressors. Curr. Opin. Cell Biol. 22:226-33
123. Liu EY, Xu N, O'Prey J, Lao LY, Joshi S, et al. 2015. Loss of autophagy causes a synthetic lethal deficiency in DNA repair. PNAS 112:773-78
124. Lunt SY,Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, et al. 2015. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol. Cell 57:95-107
125. Cunningham JT, MorenoMV,Lodi A, Ronen SM,Ruggero D. 2014. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell 157:1088-103
126. Webb BA, Chimenti M, Jacobson MP, Barber DL. 2011. Dysregulated pH: a perfect storm for cancer progression. Nat. Rev. Cancer 11:671-77
127. Santaguida S, Amon A. 2015. Short-and long-term effects of chromosome mis-segregation and aneuploidy. Nat. Rev. Mol. Cell Biol. 16:473-85
128. Santaguida S, AmonA. 2015. Aneuploidy triggers aTFEB-mediated lysosomal stress response. Autophagy 11:2383-84
129. Santaguida S, Vasile E, White E, Amon A. 2015. Aneuploidy-induced cellular stresses limit autophagic degradation. Genes Dev. 29:2010-21
130. Aits S, JaätteläM. 2013. Lysosomal cell death at a glance. J. Cell. Sci. 126:1905-12
131. Repnik U, C esen MH, Turk B. 2013. The endolysosomal system in cell death and survival. Cold Spring Harb. Perspect. Biol. 5:a008755
132. Liu Y, Levine B. 2015. Autosis and autophagic cell death: the dark side of autophagy. Cell Death Differ. 22:367-76
133. Huang S, Jia K, Wang Y, Zhou Z, Levine B. 2013. Autophagy genes function in apoptotic cell corpse clearance during C. Elegans embryonic development. Autophagy 9:138-49
134. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, et al. 2005. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122:927-39
135. Fehrenbacher N, Gyrd-Hansen M, Poulsen B, Felbor U, Kallunki T, et al. 2004. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res. 64:5301-10
136. Wu YC, Horvitz HR. 1998. C. Elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180. Nature 392:501-4
137. Hengartner MO. 2001. Apoptosis: corralling the corpses. Cell 104:325-28
138. Hochreiter-Hufford A, Ravichandran KS. 2013. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb. Perspect. Biol. 5:a008748
139. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, et al. 2012. Ferroptosis: an irondependent form of nonapoptotic cell death. Cell 149:1060-72
140. Kurz T, Terman A,Gustafsson B, Brunk UT. 2008. Lysosomes in ironmetabolism, ageing and apoptosis. Histochem. Cell Biol. 129:389-406
141. Wiggins HL,Wymant JM, Solfa F,Hiscox SE, Taylor KM, et al. 2015. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochem. Pharmacol. 93:332-42
142. Yamasaki T, Terai S, Sakaida I. 2011. Deferoxamine for advanced hepatocellular carcinoma. N. Engl. J. Med. 365:576-78
143. Westermarck J, Kähäri VM. 1999. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13:781-92
144. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, et al. 2004. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5:443-53
145. Machado E, White-Gilbertson S, van de Vlekkert D, Janke L, Moshiach S, et al. 2015. Regulated lysosomal exocytosis mediates cancer progression. Sci. Adv. 1:e1500603
146. Arvatz G, Shafat I,Levy-Adam F, Ilan N, Vlodavsky I. 2011. The heparanase system and tumormetastasis: Is heparanase the seed and soil Cancer Metastasis Rev. 30:253-68
147. Mohamed MM, Sloane BF. 2006. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 6:764-75
148. Carmeliet P. 2003. Angiogenesis in health and disease. Nat. Med. 9:653-60
149. Folkman J, Watson K, Ingber D, Hanahan D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61
150. Kallunki T,Olsen OD, JaätteläM. 2013. Cancer-associated lysosomal changes: friends or foes Oncogene 32:1995-2004
151. Jiang H, Cheng XW, Shi G-P, Hu L, Inoue A, et al. 2014. Cathepsin K-mediated notch1 activation contributes to neovascularization in response to hypoxia. Nat. Commun. 5:3838
152. Im E, Venkatakrishnan A, Kazlauskas A. 2005. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol. Biol. Cell 16:3488-500
153. JoplingHM, Odell AF, Pellet-Many C, Latham AM, Frankel P, et al. 2014. Endosome-to-plasma membrane recycling of VEGFR2 receptor tyrosine kinase regulates endothelial function and blood vessel formation. Cells 3:363-85
154. Kobayashi T, Tanaka T, Toyama-Sorimachi N. 2013. How do cells optimize luminal environments of endosomes/lysosomes for efficient inflammatory responses J. Biochem. 154:491-99
155. Lindkvist B, Fajardo I, Pejler G, Borgstr öm A. 2006. Cathepsin B activates human trypsinogen 1 but not proelastase 2 or procarboxypeptidase B. Pancreatology 6:224-31
156. Wörmann SM, Algül H. 2013. Risk factors and therapeutic targets in pancreatic cancer. Front. Oncol. 3:282
157. Choi AJS, Ryter SW. 2011. Autophagy in inflammatory diseases. Int. J. Cell Biol. 2011:732798
158. White E, Karp C, Strohecker AM, Guo Y, Mathew R. 2010. Role of autophagy in suppression of inflammation and cancer. Curr. Opin. Cell Biol. 22:212-17
159. He Y, Xu Y, Zhang C, Gao X, Dykema KJ, et al. 2011. Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci. Signal. 4:ra44
160. Kach J, Conzen SD, Szmulewitz RZ. 2015. Targeting the glucocorticoid receptor in breast and prostate cancers. Sci. Transl. Med. 7:305-19
161. Abduljabbar R, Negm OH, Lai C-F, Jerjees DA, Al-Kaabi M, et al. 2015. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast Cancer Res. Treat. 150:335-46
162. Kassi E, Moutsatsou P. 2011. Glucocorticoid receptor signaling and prostate cancer. Cancer Lett. 302:1-10
163. Lu Y-S, Lien H-C, Yeh P-Y, Kuo S-H, ChangW-C, et al. 2006. Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer 53:303-10
164. Lyon M, Rushton G, Gallagher JT. 1997. The interaction of the transforming growth factor-s with heparin/heparan sulfate is isoform-specific. J. Biol. Chem. 272:18000-6
165. Akbarshahi H, Axelsson JBF, Said K, Malmstr öm A, Fischer H, Andersson R. 2011. TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J. Transl. Med. 9:219
166. Nakajima M, IrimuraT,Di FerranteN,Nicolson GL. 1984. Metastatic melanoma cell heparanase: characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J. Biol. Chem. 259:2283-90
167. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, et al. 2011. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br. J. Cancer 104:635-42
168. Winterhoff B, Freyer L, Hammond E, Giri S, Mondal S, et al. 2015. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur. J. Cancer 51:879-92
169. Lan YY, Londõ no D, Bouley R, Rooney MS, Hacohen N. 2014. Dnase2a deficiency uncovers lysosomal clearance of damaged nuclear DNA via autophagy. Cell Rep. 9:180-92
170. Münz C. 2010. Antigen processing via autophagy-not only for MHC class II presentation anymore Curr. Opin. Immunol. 22:89-93
171. Chen H-Y,White E. 2011. Role of autophagy in cancer prevention. Cancer Prev. Res. 4:973-83
172. Lau A, Wang X-J, Zhao F, Villeneuve NF, Wu T, et al. 2010. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol. Cell Biol. 30:3275-85
173. Saitoh T, Akira S. 2010. Regulation of innate immune responses by autophagy-related proteins. J. Cell Biol. 189:925-35
174. Intlekofer AM, Thompson CB. 2013. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 94:25-39
175. Walker LSK, Sansom DM. 2015. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 36:63-70
176. Blott EJ, Griffiths GM. 2002. Secretory lysosomes. Nat. Rev. Mol. Cell Biol. 3:122-31
177. Puleston DJ, Zhang H, Powell TJ, Lipina E, Sims S, et al. 2014. Autophagy is a critical regulator of memory CD8+ T cell formation. eLife 3:2516
178. Sakhrani NM, Padh H. 2013. Organelle targeting: third level of drug targeting. Drug Des. Devel. Ther. 7:585-99
179. Lim JP, Gleeson PA. 2011. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol. Cell Biol. 89:836-43
180. Chapel A, Kieffer-Jaquinod S, Sagne C, Verdon Q, Ivaldi C, et al. 2013. An extended proteome map of the lysosomal membrane reveals novel potential transporters. Mol. Cell. Proteom. 12:1572-88
181. Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, et al. 2011. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 17:7337-46
182. Xu H, Ren D. 2015. Lysosomal physiology. Annu. Rev. Physiol. 77:57-80
183. Okamoto K. 2014. Organellophagy: eliminating cellular building blocks via selective autophagy. J. Cell Biol. 205:435-45
184. Razaq W. 2013. Bone targeted therapies for bone metastasis in breast cancer. J. Clin. Med. 2:176-87
185. Kirby M, Yu DMT, Steven Gorrell M. 2010. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin. Sci. 118:31-41
186. Pethiyagoda CL, Welch DR, Fleming TP. 2000. Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin. Exp. Metastasis 18:391-400
187. Wesley UV, Tiwari S, Houghton AN. 2004. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int. J. Cancer 109:855-66
188. Halaby R. 2015. Role of lysosomes in cancer therapy. Res. Rep. Biol. 6:147-49
189. Boya P, Kroemer G. 2008. Lysosomal membrane permeabilization in cell death. Oncogene 27:6434-51
190. Groth-Pedersen L, JaätteläM. 2013. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett. 332:265-74
191. Mataga MA, Rosenthal S, Heerboth S, Devalapalli A, Kokolus S, et al. 2012. Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor. Anticancer Res. 32:2523-29
192. De Stefanis D, Démoz M, Dragonetti A, Houri JJ, Ogier-Denis E, et al. 1997. Differentiation-induced changes in the content, secretion, and subcellular distribution of lysosomal cathepsins in the human colon cancer HT-29 cell line. Cell Tissue Res. 289:109-17
193. Jang J-H, Baerts L, Waumans Y, Meester I, Yamada Y, et al. 2015. Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice. Clin. Exp. Metastasis 32:677-87
194. Turk B. 2006. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5:785-99
195. Besouw M, Masereeuw R, van den Heuvel L, Levtchenko E. 2013. Cysteamine: an old drug with new potential. Drug Discov. Today 18:785-92
196. Fujisawa T, Rubin B, Suzuki A, Patel PS, Gahl WA, et al. 2012. Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. PLOS ONE 7:e34437
197. Elie BT, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ, Joyce JA. 2010. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie 92:1618-24
198. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, et al. 2011. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLOS ONE 6:e21106
199. Brennan TV, Lin L, Brandstadter JD, Rendell VR, Dredge K, et al. 2016. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J. Clin. Investig. 126:207-19
200. Liao B-Y, Wang Z, Hu J, LiuW-F, Shen Z-Z, et al. 2015. PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection. Tumor Biol. 37:2987-98
201. McKenzie EA. 2007. Heparanase: a target for drug discovery in cancer and inflammation. Br. J. Pharmacol. 151:1-14
202. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, et al. 2011. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin. Cancer Res. 17:1382-93
203. Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. 2014. Chloroquine and hydroxychloroquine for cancer therapy. Mol. Cell. Oncol. 1:e29911
204. Amaravadi RK,Winkler JD. 2012. Lys05: a new lysosomal autophagy inhibitor. Autophagy 8:1383-84
205. Dufour M, Dormond-Meuwly A, Demartines N, Dormond O. 2011. Targeting the mammalian target of rapamycin (mTOR) in cancer therapy: lessons from past and future perspectives. Cancers 3:2478-500